- Home
- GALT vs RAPT Comparison
GALT vs RAPT Comparison
Compare GALT & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GALT
- RAPT
- Stock Information
- Founded
- GALT 2000
- RAPT 2015
- Country
- GALT United States
- RAPT United States
- Employees
- GALT N/A
- RAPT N/A
- Industry
- GALT Biotechnology: Pharmaceutical Preparations
- RAPT Biotechnology: Pharmaceutical Preparations
- Sector
- GALT Health Care
- RAPT Health Care
- Exchange
- GALT Nasdaq
- RAPT Nasdaq
- Market Cap
- GALT 232.3M
- RAPT 194.2M
- IPO Year
- GALT N/A
- RAPT 2019
- Fundamental
- Price
- GALT $5.37
- RAPT $16.22
- Analyst Decision
- GALT Strong Buy
- RAPT Buy
- Analyst Count
- GALT 3
- RAPT 5
- Target Price
- GALT $6.00
- RAPT $33.60
- AVG Volume (30 Days)
- GALT 301.1K
- RAPT 90.1K
- Earning Date
- GALT 11-12-2025
- RAPT 11-11-2025
- Dividend Yield
- GALT N/A
- RAPT N/A
- EPS Growth
- GALT N/A
- RAPT N/A
- EPS
- GALT N/A
- RAPT N/A
- Revenue
- GALT N/A
- RAPT N/A
- Revenue This Year
- GALT N/A
- RAPT N/A
- Revenue Next Year
- GALT N/A
- RAPT N/A
- P/E Ratio
- GALT N/A
- RAPT N/A
- Revenue Growth
- GALT N/A
- RAPT N/A
- 52 Week Low
- GALT $0.73
- RAPT $5.67
- 52 Week High
- GALT $6.55
- RAPT $26.56
- Technical
- Relative Strength Index (RSI)
- GALT 68.40
- RAPT 76.72
- Support Level
- GALT $3.93
- RAPT $11.19
- Resistance Level
- GALT $4.35
- RAPT $13.66
- Average True Range (ATR)
- GALT 0.38
- RAPT 0.83
- MACD
- GALT 0.10
- RAPT 0.44
- Stochastic Oscillator
- GALT 55.47
- RAPT 93.52
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.